DETERMINATION OF ALTRETAMINE IN HUMAN PLASMA WITH HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY

被引:4
作者
BARKER, IK
CRAWFORD, SM
FELL, AF
机构
[1] UNIV BRADFORD,SCH PHARM,CANC MED RES UNIT,BRADFORD BD7 1DP,W YORKSHIRE,ENGLAND
[2] UNIV BRADFORD,SCH PHARM,PHARMACEUT ANAL RES UNIT,BRADFORD BD7 1DP,W YORKSHIRE,ENGLAND
来源
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS | 1994年 / 660卷 / 01期
关键词
D O I
10.1016/0378-4347(94)00268-1
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A fast, simple, and sensitive isocratic HPLC method has been developed and validated for the determination of the anticancer drug altretamine in human plasma. Spiked serum samples and clinical plasma samples are extracted with acetonitrile at 4 degrees C and the precipitate removed by filtration. The plasma sample volume required (ca. 0.2 ml) is small and the total analysis time is less than 15 min per sample (including batch-wise pre-treatment). Recovery of altretamine is 99 to 106% for pooled human serum spiked with altretamine in the range 200 ng/ml to 10 mg/ml. In this concentration range, the R.S.D. varies from 1 to 8%. The limit of quantitation is ca. 150 ng/ml for an R.S.D. of 10%. The intra-day R.S.D. for human samples spiked at 5 mg/ml varied between 1.7 and 4%; the inter-day R.S.D. at this concentration was ca. 3%. A preliminary study with one patient receiving 260 mg/m2 by mouth indicated that the peak altretamine concentration was significantly lower after a standard breakfast than in the fasting state.
引用
收藏
页码:121 / 126
页数:6
相关论文
共 10 条
[1]  
AMES MM, 1979, CANCER RES, V39, P5016
[2]   HEXAMETHYLMELAMINE - PHARMACOLOGY AND MECHANISM OF ACTION [J].
AMES, MM .
CANCER TREATMENT REVIEWS, 1991, 18 :3-14
[3]  
DINCALCI M, 1978, CANCER TREAT REP, V62, P2117
[4]   INFLUENCE OF ASCITES ON THE PHARMACOKINETICS OF HEXAMETHYLMELAMINE AND N-DEMETHYLATED METABOLITES IN OVARIAN-CANCER PATIENTS [J].
DINCALCI, M ;
BEGGIOLIN, G ;
SESSA, C ;
MANGIONI, C .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1981, 17 (12) :1331-1335
[5]  
DUBOIS J, 1986, CANCER CHEMOTH PHARM, V18, P226
[6]   THE ROLE OF HEXAMETHYLMELAMINE IN THE COMBINATION CHEMOTHERAPY OF ADVANCED OVARIAN-CANCER - A COMPARISON OF HEXAMETHYLMELAMINE, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND CISPLATIN (H-CAP) VERSUS CYCLOPHOSPHAMIDE, DOXORUBICIN, AND CISPLATIN (CAP) [J].
HAINSWORTH, JD ;
JONES, HW ;
BURNETT, LS ;
JOHNSON, DH ;
GRECO, FA .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1990, 13 (05) :410-415
[7]  
MILLER KJ, 1985, CANCER CHEMOTH PHARM, V15, P49
[8]  
MORIMOTO M, 1980, CANCER RES, V40, P2762
[9]   INVIVO STUDIES WITH HEXAMETHYLMELAMINE [J].
RUTTY, CJ ;
CONNORS, TA ;
NGUYENHOANGNAM ;
DOCAOTHANG ;
HOELLINGER, H .
EUROPEAN JOURNAL OF CANCER, 1978, 14 (06) :713-720
[10]  
SELEN A, 1991, PHARM BIOEQUIVALENCE, P137